Trial intelligence / Profile preview

NGX-4010 for Postherpetic Neuralgia

NCT00300222Phase 3Completed

Sponsor
NeurogesX
Start
Mar 2006
Modality
Small Molecules
01

Overview

Phase 3, randomised, double-blind trial of capsaicin in postherpetic neuralgia (PHN) (2 arms), sponsored by NeurogesX. Primary endpoint: Percent change from baseline in average pain for the past 24 hours NPRS score (Weeks 2 to 12) at 12 weeks. Started Mar 2006; status: completed.

02

Drugs

capsaicin
03

Conditions

postherpetic neuralgia (PHN)

Beyond the preview

Go deeper on NCT00300222.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00300222.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call